NEW YORK (GenomeWeb News) – Leerink Swann today upgraded shares of Fluidigm, noting a potentially multi-billion market opportunity for single-cell gene expression tools and the recent acquisition of DVS Sciences as drivers.

In a research note, Dan Leonard raised the rating on Fluidigm to Outperform from Market Perform, and maintained a $52 price target on the South San Francisco, Calif.-based firm's stock.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.

Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.

A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.

In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more

Jun
28
Sponsored by
PerkinElmer

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.